• New BRIUMVI (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis | Morningstar

    Source: Buzz FX / 18 Sep 2024 07:46:15   America/Chicago


    [GlobeNewswire](/news/globe-newswire) New BRIUMVI (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis Infusion related reactions i
    Read more...
Share on,